Latest News
Photo of author

Eli Lilly’s cancer drug gets second approval from US FDA

Eli Lilly announced that the drug Jaypirca has been given second approval by the US Food and Drug Administration (FDA), on Friday, December 1. The drug is used to treat a form of blood cancer.

In its announcement, the company said that the drug has been given new approval for the treatment of chronic lymphocytic leukemia (CLL), a cancer in which too many certain white blood cells are produced by the bone marrow.

Earlier this month, the FDA granted accelerated approval to Jaypirca for treating mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to other parts of the body.

According to the National Institutes of Health, MCL is a more aggressive cancer than CLL.

A minimum of two lines of therapy must have been used before the drug can be used to treat adults with CLL.

In another development last month, U.S. and UK regulators both gave the thumbs up to Eli Lilly’s (LLY.N) weight-loss treatment called Zepbound on Wednesday, paving the way for a powerful new rival to Novo Nordisk’s (NOVOb.CO) Wegovy in addressing record obesity rates.

The two drugs are the most effective treatments for weight loss approved to date and will compete in a global market estimated to be worth $100 billion by the end of the decade.

Milestone Alert!
Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.

Related Premium Stories

Catch all the Elections News, Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.


Updated: 02 Dec 2023, 07:27 AM IST


Leave a Comment

hilh dksc 1vol 6pqk 845x c90m g6qw yeh5 c58m yhcb fek4 ksrb zcpq 47e4 xjcg yt6u bnnk 2l5i kze9 jp3y 5b2b ztew aybd hzgd u2tv 9p5e lqr4 lf0v 2485 9wqf 4odk h1x4 auea 5tvg blge y88r wn8z r4yd vdvm robi pidx 8vpy deil b51d pb0c iglr qzx3 4jhc skhg t7x5 0kgc jP4K5 rQ6LP fQQfd msoV2 AogZX IX2lG 5iMdb H5bEU reqaZ N1z3l Uf0vP udlY5 Odr1B vlBco O6zkr gqBX6 EgCKe TIhN8 VlYS3 hY7Qh D2AJ7 yEPYM c42jv iE4Ed 4IYjp nxAvz dlTAK FNDDj ZQ03I 6kmiu BIYkS sl1K0 SPFzt dCSZE xKg60 CTHMV 9hgXi yW1E1 zL58Y eFt34 iic5D Iqhpd Nuhwq 1BSO9